Corinne Johnson
Stock Analyst at Goldman Sachs
(1.68)
# 3,335
Out of 4,944 analysts
12
Total ratings
45.45%
Success rate
-1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $46.15 | +19.18% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $18.05 | +82.88% | 3 | Jul 10, 2025 | |
| AMLX Amylyx Pharmaceuticals | Reinstates: Buy | $10 | $8.30 | +20.48% | 1 | Jul 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $18 | $13.45 | +33.83% | 1 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $131.62 | +38.28% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $26.49 | +88.75% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $15.89 | +214.66% | 1 | Mar 13, 2024 |
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $46.15
Upside: +19.18%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $18.05
Upside: +82.88%
Amylyx Pharmaceuticals
Jul 10, 2025
Reinstates: Buy
Price Target: $10
Current: $8.30
Upside: +20.48%
Syndax Pharmaceuticals
Jul 10, 2025
Initiates: Buy
Price Target: $18
Current: $13.45
Upside: +33.83%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $131.62
Upside: +38.28%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $26.49
Upside: +88.75%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $15.89
Upside: +214.66%